8C5 Stoklara Genel Bakış Bir biyofarmasötik şirketi olan Coherus BioSciences, Inc. öncelikle Amerika Birleşik Devletleri'nde kanser tedavilerinin araştırılması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay
Ödüller Risk Analizi + 1 daha fazla risk
Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Coherus BioSciences, Inc. Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Coherus BioSciences Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı US$1.40 52 Haftanın En Yüksek Seviyesi US$3.34 52 Haftanın En Düşük Seviyesi US$0.61 Beta 0.86 1 Aylık Değişim 35.65% 3 Aylık Değişim 55.79% 1 Yıllık Değişim -22.35% 3 Yıllık Değişim -90.94% 5 Yıllık Değişim -91.43% Halka arzdan bu yana değişim -88.05%
Son Haberler & Güncellemeler
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18 Daha fazla güncelleme görün
Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carinoma at ASCO-GI 2025 Dec 19 Intas Pharmaceuticals Limited entered into asset purchase agreement to acquire UDENYCA Franchise of Coherus BioSciences, Inc. (NasdaqGM:CHRS) for $560 million. Dec 04
New major risk - Revenue and earnings growth Nov 16
No longer forecast to breakeven Nov 08
Coherus BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024 Oct 31
New minor risk - Market cap size Oct 18
Forecast breakeven date pushed back to 2025 Aug 11
Second quarter 2024 earnings released: US$0.11 loss per share (vs US$0.49 loss in 2Q 2023) Aug 09
Coherus BioSciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
New major risk - Share price stability Jul 02
Coherus BioSciences, Inc. Appoints Rita Karachun to Its Board of Directors Jun 06
Coherus Biosciences, Inc. Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-Chemokine Receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting May 24
Forecast breakeven date moved forward to 2024 May 12
First quarter 2024 earnings released: EPS: US$0.91 (vs US$0.95 loss in 1Q 2023) May 10 Coherus BioSciences, Inc. announced that it has received $38.7 million in funding May 10
Coherus BioSciences, Inc. Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI®? (toripalimab-tpzi) with ENB-003 for the Treatment of Ovarian Cancer May 09
Coherus BioSciences, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Coherus BioSciences, Inc. Announces Presentation of Clinical Data for CHS-114 at 2024 American Society of Clinical Oncology Annual Meeting Apr 24
Coherus BioSciences, Inc., Annual General Meeting, May 29, 2024 Apr 16
Full year 2023 earnings released: US$2.53 loss per share (vs US$3.76 loss in FY 2022) Mar 14
Forecast breakeven date pushed back to 2026 Mar 14
Coherus BioSciences, Inc. to Report Q4, 2023 Results on Mar 13, 2024 Mar 06
New major risk - Financial position Feb 28
Coherus BioSciences, Inc. Announces U.S. Launch of UDENYCA ONBODY a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Feb 22 Sandoz Group AG (SWX:SDZ) entered into a definitive agreement to acquire CIMERLI an ophthalmology franchise from Coherus BioSciences, Inc. (NasdaqGM:CHRS) for approximately $170 million. Jan 22
Coherus BioSciences, Inc. Presents Positive Phase 2 Clinical Data on Casdozokitug, A First-In-Class IL-27-Targeted Antibody, At the 2024 ASCO GI Cancers Symposium Jan 19
Coherus Announces FDA Approval of UDENYCA ONBODY™, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv Dec 27 Coherus BioSciences, Inc. Appoints Bryan McMichael as Principal Financial Officer
Coherus BioSciences, Inc. Announces Resignation of McDavid Stilwell as Chief Financial Officer, Effective December 31, 2023 Dec 08
Coherus BioSciences, Inc. Presents Phase 1/2 Clinical Data on Casdozokitug at the 2023 ESMO Immuno-Oncology Congress Dec 06
Coherus and Junshi Biosciences Announces Publication of Positive Final Overall Survival Results of Jupiter-02, A Phase 3 Trial Evaluating Loqtorzi (Toripalimab-Tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical Association Nov 29 Coherus Biosciences, Inc. Lowers Its Revenue Guidance for 2023 Nov 08
Third quarter 2023 earnings released: US$0.41 loss per share (vs US$1.12 loss in 3Q 2022) Nov 07 Coherus BioSciences, Inc. to Report Q3, 2023 Results on Nov 06, 2023
Coherus Biosciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Biosciences Announce FDA Approval of Loqtorzi (Toripalimab-Tpzi) in All Lines of Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Oct 28
Coherus BioSciences, Inc. Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 16
Coherus Biosciences, Inc. Announces Resubmission of Biologics License Application (Bla) Supplement for Udenyca(R) Onbody Oct 06
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus BioSciences, Inc Also Announces Completion of Toripalimab FDA Inspections Sep 26
Coherus BioSciences, Inc. (NasdaqGM:CHRS) completed the acquisition of Surface Oncology, Inc. (NasdaqGM : SURF) from Novartis Institutes for BioMedical Research, Inc., Atlas Venture Fund IX, L.P., managed by Atlas Venture L.P., ARK Investment Management LLC, EcoR1 Capital, LLC and others. Sep 09
Second quarter 2023 earnings released: US$0.49 loss per share (vs US$0.65 loss in 2Q 2022) Aug 03
Coherus Biosciences, Inc. Provides Revenue Guidance for the Year 2023 Aug 03
Coherus BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023 Jul 28
Coherus Biosciences, Inc. Announces Appointment of Michael Ryan to Board of Directors Jul 23
Coherus Launches Yusimry™, A Biosimilar of Humira® Jul 04 Coherus BioSciences, Inc. (NasdaqGM:CHRS) entered into a definitive merger agreement to acquire Surface Oncology, Inc. (NasdaqGM : SURF) for transaction value of $65 million. Jun 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 18
Coherus BioSciences, Inc. has completed a Follow-on Equity Offering in the amount of $50.000001 million. May 17
Coherus BioSciences, Inc. Provides Earnings Guidance for the Full Year 2023 May 10
First quarter 2023 earnings released: US$0.95 loss per share (vs US$1.24 loss in 1Q 2022) May 09
Full year 2022 earnings released: US$3.76 loss per share (vs US$3.81 loss in FY 2021) Mar 08
Shanghai Junshi Biosciences Co., Ltd and Coherus Biosciences, Inc. Announce Positive Results of A Final Analysis of Overall Survival from the Pivotal Study JUPITER-02 Feb 16
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma Dec 26
High number of new and inexperienced directors Nov 16
Third quarter 2022 earnings released: US$1.12 loss per share (vs US$0.49 loss in 3Q 2021) Nov 10
Coherus BioSciences, Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology Oct 13
Coherus to Launch Cimerli (Ranibizumab-Eqrn) in the United States on October 3, 2022 Sep 20
Coherus BioSciences, Inc. Announces Executive Changes Sep 10
Second quarter 2022 earnings released: US$0.65 loss per share (vs US$0.40 loss in 2Q 2021) Aug 05
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity Aug 03
Coherus BioSciences, Inc. to Report Q2, 2022 Results on Aug 04, 2022 Jul 29
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Jul 07
Coherus BioSciences Appoints Jill O’Donnell-Tormey to Its Board of Directors, Nominating and Corporate Governance Committee of the Board of Directors May 12
First quarter 2022 earnings released: US$1.24 loss per share (vs US$2.38 loss in 1Q 2021) May 07
Coherus Biosciences, Inc. Appoints Charlie Newton to Board of Directors, Member of Audit Committee May 06
Coherus BioSciences, Inc. to Report Q1, 2022 Results on May 05, 2022 May 02
High number of new and inexperienced directors Apr 27
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting Apr 09
Coherus BioSciences, Inc., Annual General Meeting, May 17, 2022 Apr 05
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. Announce Positive Results from Phase 3 Esophageal Cancer Study of Toripalimab Published in Cancer Cell Mar 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 18
Coherus BioSciences, Inc. Appoints Paul Reider as Chief Commercial Officer Feb 16
Coherus BioSciences, Inc. to Report Q4, 2021 Results on Feb 17, 2022 Feb 12
Coherus BioSciences, Inc. Announces Management Changes Feb 08
Coherus BioSciences, Inc. Announces U.S. FDA Approval of YUSIMRY Dec 21
Shanghai Junshi Biosciences Co., Ltd. and Coherus BioSciences, Inc. Announce Positive Interim Overall Survival Results of CHOICE-01, A Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer Dec 15
Third quarter 2021 earnings released: US$0.49 loss per share (vs US$0.39 profit in 3Q 2020) Nov 09
Positive Interim Results of CHOICE-01 Study Evaluating Coherus' and Junshi Biosciences’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer Sep 15
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Completion of Rolling BLA Submission to U.S. FDA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma Sep 02
Shanghai Junshi Biosciences Co., Ltd. and Coherus Biosciences, Inc. Announce Positive Interim Results from the Pivotal Study Choice-01 Aug 20
Junshi Biosciences and Coherus Announce U.S. FDA Breakthrough Therapy Designation Granted for Toripalimab for 1st Line Treatment of Nasopharyngeal Carcinoma Aug 13
Independent Director Mary Szela has left the company Aug 12
Second quarter 2021 earnings released: US$0.40 loss per share (vs US$0.83 profit in 2Q 2020) Aug 08 Hissedar Getirileri 8C5 DE Biotechs DE Pazar 7D -8.4% -2.9% -2.6% 1Y -22.3% -14.7% 6.9%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 8C5 geçen yıl % -14.7 oranında getiri sağlayan German Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: 8C5 geçen yıl % 6.9 oranında getiri sağlayan German Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 8C5's price volatile compared to industry and market? 8C5 volatility 8C5 Average Weekly Movement 24.8% Biotechs Industry Average Movement 6.8% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
İstikrarlı Hisse Senedi Fiyatı: 8C5 hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: 8C5 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 16% dan 25% a yükseldi.
Şirket Hakkında Bir biyofarmasötik şirketi olan Coherus BioSciences, Inc. öncelikle Amerika Birleşik Devletleri'nde kanser tedavilerinin araştırılması, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, uzun etkili bir granülosit-koloni uyarıcı faktör olan Neulasta'ya biyobenzer UDENYCA'yı; yeni bir PD-1 inhibitörü olan LOQTORZI'yi ve interlökin 27'yi hedefleyen araştırma amaçlı bir rekombinant insan immünoglobulin izotip G1 (IgG1) monoklonal antikoru olan Casdozokitug'u geliştirmektedir. Ayrıca, tümör mikroçevresindeki (TME) Treg hücrelerinde yüksek oranda eksprese edilen bir kemokin reseptörü olan CCR8'i seçici olarak hedefleyen, araştırma amaçlı, oldukça spesifik bir insan afukozillenmiş IgG1 monoklonal antikoru olan CHS-114'ü ve elverişsiz bir TME'yi daha elverişli bir TME'ye dönüştürerek anti-PD-1 klinik faydasını iyileştirmek için tasarlanmış insan ILT4'ü hedefleyen bir antikor olan CHS-1000'i geliştirmektedir.
Daha fazla göster Coherus BioSciences, Inc. Temel Bilgiler Özeti Coherus BioSciences'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 8C5 temel i̇stati̇sti̇kler Piyasa değeri €167.84m Kazançlar(TTM ) -€431.28k Gelir(TTM ) €291.68m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 8C5 gelir tablosu (TTM ) Gelir US$304.34m Gelir Maliyeti US$168.26m Brüt Kâr US$136.08m Diğer Giderler US$136.53m Kazançlar -US$450.00k
Son Raporlanan Kazançlar
Sep 30, 2024
Hisse başına kazanç (EPS) -0.0039 Brüt Marj 44.71% Net Kâr Marjı -0.15% Borç/Özkaynak Oranı -300.7%
8C5 uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/22 02:27 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Coherus BioSciences, Inc. 17 Bu analistlerden 7, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Colleen Kusy Baird Balaji Prasad Barclays Balaji Prasad Barclays
Göster 14 daha fazla analist 
